

DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Immunosuppressive Agents – Rezurock Drug Quantity Management Policy – Per Rx

- Rezurock™ (belumosudil tablets – Kadmon)

REVIEW DATE: 09/14/2022

OVERVIEW

Rezurock, a kinase inhibitor, is indicated for the treatment of patients ≥ 12 years of age with **chronic graft-versus-host disease (GVHD)** after failure of at least two prior lines of systemic therapy.¹

Dosing

The recommended dose of Rezurock is 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy.¹ Rezurock tablets should be swallowed whole; do not cut, crush, or chew. The dose of Rezurock should be increased to 200 mg twice daily when it is co-administered with strong cytochrome P450(CYP)3A inducers or proton pump inhibitors.

Availability

Rezurock is available as 200 mg tablets in bottles of 30.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to prevent stockpiling and waste, and address potential order entry error of Rezurock. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per Rx*	Home Delivery Maximum Quantity per Rx
Rezurock™ (belumosudil tablets)	200 mg tablets	30 tablets	90 tablets

* Based on prescribing information, 30 of the 200 mg tablets are adequate for a 30-day supply. Exceptions can be made for patients taking strong cytochrome P450 (CYP)3A inducers or proton pump inhibitors.

CRITERIA

1. If the patient is taking Rezurock with a strong cytochrome P450(CYP)3A inducer OR with a proton pump inhibitor, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: CYP3A4 inducers include, but are not limited to, rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and St. John's Wort. Examples of proton pump inhibitors include, but are not limited to, lansoprazole, omeprazole, rabeprazole, esomeprazole, pantoprazole, and dexlansoprazole.

REFERENCES

1. Rezurock™ tablets [prescribing information]. Warrendale, PA: Kadmon; July 2021.

09/14/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

